A new device that promises to significantly ease the administration of human growth hormones (HGH) has been launched in the UK.
SurePal is a new injection device for the treatment Omnitrope HGH, which is currently received by more than 800 UK patients with growth disorders.
The device uses cartridges that require no reconstitution or priming, and a sliding injection button that requires minimum force to operate, according to its manufacturer Sandoz.
Safety features include non-interchangeable dose-specific cartridges, a dose memory function that remembers daily doses and a robust needle hider to reduce anxiety for patients afraid of needles.
Peter Laing, paediatric advanced nurse practitioner endocrinology at Alder Hey Children’s Foundation Trust, suggested the product represented a “quantum leap” for HGH patients.
He said: “Patients treated with growth hormone therapy require an injection of HGH on a daily basis, which requires significant commitment from the individual, parent or primary caregiver.
“Therefore, ease of use and simplicity of the growth hormone device combined with features of added patient safety are essential to ensure good treatment outcomes,” he said.
Are you able to Speak Out Safely? Sign our petition to put pressure on your trust to support an open and transparent NHS.